UCBJY Quote, Financials, Valuation and Earnings

Celyad Oncology SA has a net margin of -- compared to UCB SA's net margin of --. UCB SA's return on equity of 13.88% beat Celyad Oncology SA's return on equity of --.

UCB SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Celyad Oncology SA has an analysts' consensus of -- which suggests that it could fall by --. Given that UCB SA has higher upside potential than Celyad Oncology SA, analysts believe UCB SA is more attractive than Celyad Oncology SA.

UCB SA has a beta of 0.675, which suggesting that the stock is 32.475% less volatile than S&P 500. In comparison Celyad Oncology SA has a beta of 0.162, suggesting its less volatile than the S&P 500 by 83.796%.

UCB SA has a quarterly dividend of $0.79 per share corresponding to a yield of 0.55%. Celyad Oncology SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. UCB SA pays 15.96% of its earnings as a dividend. Celyad Oncology SA pays out -- of its earnings as a dividend. UCB SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

UCB SA quarterly revenues are --, which are smaller than Celyad Oncology SA quarterly revenues of --. UCB SA's net income of -- is lower than Celyad Oncology SA's net income of --. Notably, UCB SA's price-to-earnings ratio is 38.71x while Celyad Oncology SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for UCB SA is 7.52x versus 37.01x for Celyad Oncology SA. Usually stocks with elevated PS ratios are considered overvalued.

Galapagos NV has a net margin of -- compared to UCB SA's net margin of -286.67%. UCB SA's return on equity of 13.88% beat Galapagos NV's return on equity of -16.48%.

UCB SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Galapagos NV has an analysts' consensus of $27.45 which suggests that it could fall by -13.07%. Given that Galapagos NV has higher upside potential than UCB SA, analysts believe Galapagos NV is more attractive than UCB SA.

UCB SA has a beta of 0.675, which suggesting that the stock is 32.475% less volatile than S&P 500. In comparison Galapagos NV has a beta of 0.185, suggesting its less volatile than the S&P 500 by 81.495%.

UCB SA has a quarterly dividend of $0.79 per share corresponding to a yield of 0.55%. Galapagos NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. UCB SA pays 15.96% of its earnings as a dividend. Galapagos NV pays out -- of its earnings as a dividend. UCB SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

UCB SA quarterly revenues are --, which are smaller than Galapagos NV quarterly revenues of $83.2M. UCB SA's net income of -- is lower than Galapagos NV's net income of -$238.4M. Notably, UCB SA's price-to-earnings ratio is 38.71x while Galapagos NV's PE ratio is 21.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for UCB SA is 7.52x versus 6.57x for Galapagos NV. Usually stocks with elevated PS ratios are considered overvalued.

MDxHealth SA has a net margin of -- compared to UCB SA's net margin of -29.2%. UCB SA's return on equity of 13.88% beat MDxHealth SA's return on equity of -548.42%.

UCB SA has a consensus price target of --, signalling downside risk potential of --. On the other hand MDxHealth SA has an analysts' consensus of $7.0400 which suggests that it could grow by 95.56%. Given that MDxHealth SA has higher upside potential than UCB SA, analysts believe MDxHealth SA is more attractive than UCB SA.

UCB SA has a beta of 0.675, which suggesting that the stock is 32.475% less volatile than S&P 500. In comparison MDxHealth SA has a beta of -557,066.812, suggesting its less volatile than the S&P 500 by 55706781.163%.

UCB SA has a quarterly dividend of $0.79 per share corresponding to a yield of 0.55%. MDxHealth SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. UCB SA pays 15.96% of its earnings as a dividend. MDxHealth SA pays out -- of its earnings as a dividend. UCB SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

UCB SA quarterly revenues are --, which are smaller than MDxHealth SA quarterly revenues of $27.4M. UCB SA's net income of -- is lower than MDxHealth SA's net income of -$8M. Notably, UCB SA's price-to-earnings ratio is 38.71x while MDxHealth SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for UCB SA is 7.52x versus 1.72x for MDxHealth SA. Usually stocks with elevated PS ratios are considered overvalued.

Nyxoah SA has a net margin of -- compared to UCB SA's net margin of -1195.73%. UCB SA's return on equity of 13.88% beat Nyxoah SA's return on equity of -96.48%.

UCB SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Nyxoah SA has an analysts' consensus of $11.23 which suggests that it could grow by 129.58%. Given that Nyxoah SA has higher upside potential than UCB SA, analysts believe Nyxoah SA is more attractive than UCB SA.

UCB SA has a beta of 0.675, which suggesting that the stock is 32.475% less volatile than S&P 500. In comparison Nyxoah SA has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

UCB SA has a quarterly dividend of $0.79 per share corresponding to a yield of 0.55%. Nyxoah SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. UCB SA pays 15.96% of its earnings as a dividend. Nyxoah SA pays out -- of its earnings as a dividend. UCB SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

UCB SA quarterly revenues are --, which are smaller than Nyxoah SA quarterly revenues of $2.3M. UCB SA's net income of -- is lower than Nyxoah SA's net income of -$27.6M. Notably, UCB SA's price-to-earnings ratio is 38.71x while Nyxoah SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for UCB SA is 7.52x versus 29.02x for Nyxoah SA. Usually stocks with elevated PS ratios are considered overvalued.